{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:35:38Z","timestamp":1783524938646,"version":"3.55.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with \u2265 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with \u2265 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models.<\/jats:p>","DOI":"10.1371\/journal.pone.0332703","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:33:04Z","timestamp":1759167184000},"page":"e0332703","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["New estimates of the costs of adverse events in patients with cancer"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4803-3540","authenticated-orcid":true,"given":"Achal","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-4897","authenticated-orcid":true,"given":"Robert","family":"Schuldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Sussell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"2","key":"pone.0332703.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","article-title":"A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]","volume":"21","author":"Jr Garrison LP","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"pone.0332703.ref002","first-page":"158","article-title":"Economic burden associated with adverse events in patients with metastatic melanoma","volume":"21","author":"B Arondekar","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"31","key":"pone.0332703.ref003","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011736","article-title":"Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review","volume":"97","author":"C Copley-Merriman","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0332703.ref004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oncolo\/oyac186","article-title":"Grade 3\/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma","volume":"28","author":"B McGregor","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"pone.0332703.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"W Wong","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"pone.0332703.ref006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/pharma2020012","article-title":"Cost estimations of managing adverse drug reactions in hospitalized patients: a systematic review of study methods and their influences","volume":"2","author":"SF Abu","year":"2023","journal-title":"Pharmacoepidemiology"},{"issue":"1","key":"pone.0332703.ref007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13561-024-00481-y","article-title":"Evaluating the costs of adverse drug events in hospitalized patients: a systematic review","volume":"14","author":"M Durand","year":"2024","journal-title":"Health Econ Rev"},{"issue":"5","key":"pone.0332703.ref008","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","author":"CW Shepard","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"pone.0332703.ref009","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2007.08.056","article-title":"Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis","volume":"107","author":"EL Jewell","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"6","key":"pone.0332703.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199598","article-title":"The burden of out of pocket costs and medical debt faced by households with chronic health conditions in the United States","volume":"13","author":"P Richard","year":"2018","journal-title":"PLoS One"},{"key":"pone.0332703.ref011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2018.02.011","article-title":"Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy","volume":"119","author":"H Borghaei","year":"2018","journal-title":"Lung Cancer"},{"key":"pone.0332703.ref012","article-title":"Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC)","volume":"27","author":"YM Yim","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"pone.0332703.ref013","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13696998.2016.1192548","article-title":"Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries","volume":"19","author":"DE Irwin","year":"2016","journal-title":"J Med Econ"},{"issue":"5","key":"pone.0332703.ref014","article-title":"Healthcare costs related to adverse events in hepatocellular carcinoma treatment: a retrospective observational claims study","volume":"5","author":"LS Lal","year":"2022","journal-title":"Cancer Reports"},{"issue":"33","key":"pone.0332703.ref015","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.2217\/fon-2019-0434","article-title":"Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA","volume":"15","author":"P Grivas","year":"2019","journal-title":"Future Oncol"},{"key":"pone.0332703.ref016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/2193-1801-3-259","article-title":"Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens","volume":"3","author":"RN Hansen","year":"2014","journal-title":"Springerplus"},{"issue":"1","key":"pone.0332703.ref017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13696998.2016.1225577","article-title":"The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States","volume":"20","author":"D Latremouille-Viau","year":"2017","journal-title":"J Med Econ"},{"issue":"7","key":"pone.0332703.ref018","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13812","article-title":"The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors","volume":"26","author":"S George","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"pone.0332703.ref019","first-page":"729","article-title":"Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer","volume":"26","author":"NM Engel-Nitz","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"pone.0332703.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.05.016","article-title":"Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer","volume":"19","author":"A Arunachalam","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:33:09Z","timestamp":1759167189000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332703"}},"subtitle":[],"editor":[{"given":"Monia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}